Cargando…
Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer
PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644202/ https://www.ncbi.nlm.nih.gov/pubmed/23400506 http://dx.doi.org/10.1007/s00259-013-2348-4 |
_version_ | 1782268430877982720 |
---|---|
author | Choi, Noah C. Chun, Tristen T. Niemierko, Andrzej Ancukiewicz, Marek Fidias, Panos M. Kradin, Richard L. Mathisen, Douglas J. Lynch, Thomas J. Fischman, Alan J. |
author_facet | Choi, Noah C. Chun, Tristen T. Niemierko, Andrzej Ancukiewicz, Marek Fidias, Panos M. Kradin, Richard L. Mathisen, Douglas J. Lynch, Thomas J. Fischman, Alan J. |
author_sort | Choi, Noah C. |
collection | PubMed |
description | PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression. RESULTS: We accrued 106 patients, of whom 61 completed the serial (18)F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g for tumors with local control and 0.12, 0.16 and 0.19 μmol/min/g for tumors with local failure, and the maximum standard uptake values (SUVmax) were 1.16, 1.33 and 1.45 for tumors with local control and 2.74, 2.74 and 4.07 for tumors with local failure (p < 0.0001). MRglc-MMR was realized at S2 (MRglc-S2) and the values corresponding to TCP 95 %, 90 % and 50 % were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and 0.70, 0.91 and 1.95 using SUVmax, respectively. Probability cut-off values were generated for a given level of MRglc-S2 based on its predicted TCP, sensitivity and specificity, and MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were determined as the optimum cut-off values for predicted TCP 80 %, sensitivity 100 % and specificity 63 %. CONCLUSION: The cut-off values (MRglc ≤0.071 μmol/min/g using the SKM and SUVmax ≤1.45) need to be tested for their utility in identifying patients with a high risk of residual cancer after standard dose radiotherapy or chemoradiotherapy and in guiding a timely supplementary dose of radiation or other means of salvage therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-013-2348-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3644202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-36442022013-05-06 Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer Choi, Noah C. Chun, Tristen T. Niemierko, Andrzej Ancukiewicz, Marek Fidias, Panos M. Kradin, Richard L. Mathisen, Douglas J. Lynch, Thomas J. Fischman, Alan J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: We investigated the metabolic response of lung cancer to radiotherapy or chemoradiotherapy by (18)F-FDG PET and its utility in guiding timely supplementary therapy. METHODS: Glucose metabolic rate (MRglc) was measured in primary lung cancers during the 3 weeks before, and 10–12 days (S2), 3 months (S3), 6 months (S4), and 12 months (S5) after radiotherapy or chemoradiotherapy. The association between the lowest residual MRglc representing the maximum metabolic response (MRglc-MMR) and tumor control probability (TCP) at 12 months was modeled using logistic regression. RESULTS: We accrued 106 patients, of whom 61 completed the serial (18)F-FDG PET scans. The median values of MRglc at S2, S3 and S4 determined using a simplified kinetic method (SKM) were, respectively, 0.05, 0.06 and 0.07 μmol/min/g for tumors with local control and 0.12, 0.16 and 0.19 μmol/min/g for tumors with local failure, and the maximum standard uptake values (SUVmax) were 1.16, 1.33 and 1.45 for tumors with local control and 2.74, 2.74 and 4.07 for tumors with local failure (p < 0.0001). MRglc-MMR was realized at S2 (MRglc-S2) and the values corresponding to TCP 95 %, 90 % and 50 % were 0.036, 0.050 and 0.134 μmol/min/g using the SKM and 0.70, 0.91 and 1.95 using SUVmax, respectively. Probability cut-off values were generated for a given level of MRglc-S2 based on its predicted TCP, sensitivity and specificity, and MRglc ≤0.071 μmol/min/g and SUVmax ≤1.45 were determined as the optimum cut-off values for predicted TCP 80 %, sensitivity 100 % and specificity 63 %. CONCLUSION: The cut-off values (MRglc ≤0.071 μmol/min/g using the SKM and SUVmax ≤1.45) need to be tested for their utility in identifying patients with a high risk of residual cancer after standard dose radiotherapy or chemoradiotherapy and in guiding a timely supplementary dose of radiation or other means of salvage therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-013-2348-4) contains supplementary material, which is available to authorized users. Springer-Verlag 2013-02-12 2013 /pmc/articles/PMC3644202/ /pubmed/23400506 http://dx.doi.org/10.1007/s00259-013-2348-4 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Choi, Noah C. Chun, Tristen T. Niemierko, Andrzej Ancukiewicz, Marek Fidias, Panos M. Kradin, Richard L. Mathisen, Douglas J. Lynch, Thomas J. Fischman, Alan J. Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
title | Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
title_full | Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
title_fullStr | Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
title_full_unstemmed | Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
title_short | Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
title_sort | potential of (18)f-fdg pet toward personalized radiotherapy or chemoradiotherapy in lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3644202/ https://www.ncbi.nlm.nih.gov/pubmed/23400506 http://dx.doi.org/10.1007/s00259-013-2348-4 |
work_keys_str_mv | AT choinoahc potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT chuntristent potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT niemierkoandrzej potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT ancukiewiczmarek potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT fidiaspanosm potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT kradinrichardl potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT mathisendouglasj potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT lynchthomasj potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer AT fischmanalanj potentialof18ffdgpettowardpersonalizedradiotherapyorchemoradiotherapyinlungcancer |